Emerging therapies in thoracic malignancies— immuno the rapy, targe ted the rapy, and t-cell the rapy in non–small cell lung cancer

dc.creatorSepesi, Boris
dc.creatorCascone, Tina
dc.creatorChun, Stephen G.
dc.creatorAltan, Mehmet
dc.creatorLe, Xiuning
dc.date.accessioned2020-08-11T14:10:12Z
dc.date.accessioned2022-09-23T18:35:09Z
dc.date.available2020-08-11T14:10:12Z
dc.date.available2022-09-23T18:35:09Z
dc.date.created2020-08-11T14:10:12Z
dc.identifier1055-3207
dc.identifierhttps://doi.org/10.1016/j.soc.2020.06.009
dc.identifierhttp://hdl.handle.net/20.500.12010/11823
dc.identifierhttps://doi.org/10.1016/j.soc.2020.06.009
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3503638
dc.description.abstractOver the past decade there have been dramatic therapeutic advances for non–small cell lung cancer (NSCLC) that have been based on an improved understanding of biomarkers, tumor immunology, driver mutations, T-cell receptors (TCRs), and adoptive immune therapies. As a result of these advances, the overall survival (OS) currently seen with immunotherapy and targeted biologic regimens is remarkably longer than with historic cytotoxic chemotherapy. These discoveries have created many new possible therapeutic options for lung cancer patients in both local and metastatic settings. This article reviews the current landscape of immunotherapy, targeted therapy, and adoptive therapy in NSCLC.
dc.publisherSurgical Oncology Clinics of North America
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.rightsAcceso restringido
dc.sourcereponame:Expeditio Repositorio Institucional UJTL
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozano
dc.subjectImmunotherapy
dc.subjectTargeted therapy
dc.subjectT cells
dc.subjectAdoptive therapy
dc.subjectNon–small cell lung cancer
dc.titleEmerging therapies in thoracic malignancies— immuno the rapy, targe ted the rapy, and t-cell the rapy in non–small cell lung cancer


Este ítem pertenece a la siguiente institución